IL97191A0 - Novel benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists,methods of preparation,synthesis intermediates and pharmaceutical compositions containing them - Google Patents

Novel benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists,methods of preparation,synthesis intermediates and pharmaceutical compositions containing them

Info

Publication number
IL97191A0
IL97191A0 IL97191A IL9719191A IL97191A0 IL 97191 A0 IL97191 A0 IL 97191A0 IL 97191 A IL97191 A IL 97191A IL 9719191 A IL9719191 A IL 9719191A IL 97191 A0 IL97191 A0 IL 97191A0
Authority
IL
Israel
Prior art keywords
radical
lower alkyl
group
hydrogen atom
cycloalkyl
Prior art date
Application number
IL97191A
Other languages
English (en)
Original Assignee
Union Pharma Scient Appl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Union Pharma Scient Appl filed Critical Union Pharma Scient Appl
Publication of IL97191A0 publication Critical patent/IL97191A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/6506Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
IL97191A 1990-02-16 1991-02-08 Novel benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists,methods of preparation,synthesis intermediates and pharmaceutical compositions containing them IL97191A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9001925A FR2658511B1 (fr) 1990-02-16 1990-02-16 Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
IL97191A0 true IL97191A0 (en) 1992-05-25

Family

ID=9393829

Family Applications (2)

Application Number Title Priority Date Filing Date
IL9719195A IL97191A (en) 1990-02-16 1991-02-08 History of benzimidazole and abenzimidazole which are antagonists of thromboxane receptors Methods of preparation and preparations containing them
IL97191A IL97191A0 (en) 1990-02-16 1991-02-08 Novel benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists,methods of preparation,synthesis intermediates and pharmaceutical compositions containing them

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL9719195A IL97191A (en) 1990-02-16 1991-02-08 History of benzimidazole and abenzimidazole which are antagonists of thromboxane receptors Methods of preparation and preparations containing them

Country Status (18)

Country Link
US (2) US5021443A (es)
EP (1) EP0442820B1 (es)
JP (1) JPH05155858A (es)
KR (1) KR910021382A (es)
AT (1) ATE127794T1 (es)
AU (1) AU638096B2 (es)
CA (1) CA2035710A1 (es)
DE (1) DE69112863T2 (es)
DK (1) DK0442820T3 (es)
ES (1) ES2080919T3 (es)
FR (1) FR2658511B1 (es)
GR (1) GR3018000T3 (es)
IE (1) IE910339A1 (es)
IL (2) IL97191A (es)
LV (1) LV11028B (es)
NZ (1) NZ237121A (es)
PT (1) PT96792A (es)
ZA (1) ZA911061B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128359A (en) * 1990-02-16 1992-07-07 Laboratoires Upsa Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation
DE4200954A1 (de) * 1991-04-26 1992-10-29 Bayer Ag Heterocyclisch substituierte phenylessigsaeurederivate
TW300219B (es) * 1991-09-14 1997-03-11 Hoechst Ag
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
US5468757A (en) * 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
ATE253073T1 (de) 1997-03-07 2003-11-15 Metabasis Therapeutics Inc Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase
EP1402895A1 (en) * 1997-03-07 2004-03-31 Metabasis Therapeutics, Inc. Benzimidazole inhibitors of fructose 1,6-biphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
SK9192000A3 (en) * 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
TR200100047T2 (tr) * 1998-07-15 2001-10-22 Teijin Limited Tiyobenzimidazol türevleri
US20050267148A1 (en) * 1998-07-15 2005-12-01 Teijin Limited Benzimidazole derivative
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
CA2365118A1 (en) * 2000-01-17 2001-07-26 Teijin Limited Inhibitor against human chymase activity
WO2001089519A1 (en) * 2000-05-22 2001-11-29 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
CA2441177A1 (en) * 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
CN101433717A (zh) * 2001-08-24 2009-05-20 帝人株式会社 含有食糜酶抑制剂和ace抑制剂作为有效成分的药物
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2002368133A1 (en) * 2002-07-29 2004-02-16 Shizuoka Coffein Co., Ltd. 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004032861A2 (en) * 2002-10-11 2004-04-22 Bristol-Myers Squibb Company Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
JP2007501618A (ja) * 2003-08-08 2007-02-01 アバニール・ファーマシューティカルズ タンパク質輸送の選択的薬理学的阻害、および関連した、ヒト疾患を治療する方法
DE102004027821A1 (de) * 2004-06-08 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzimidazole, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP4953455B2 (ja) * 2004-09-30 2012-06-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター(sarm)として有用な新規なベンゾイミダゾール誘導体
TW200916098A (en) * 2007-06-14 2009-04-16 Teijin Pharma Ltd Agent for lowering uric acid level
WO2012009545A1 (en) * 2010-07-14 2012-01-19 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
JP6256469B2 (ja) * 2012-08-03 2018-01-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ[2.5]オクタン−5,7−ジオンの調製プロセス
WO2014151367A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv 1,2,5-substituted benzimidazoles as flap modulators
WO2014151380A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv 1,2,6-substituted benzimidazoles as flap modulators
AU2019294083A1 (en) * 2018-06-25 2021-01-21 Suzhou Mednes Pharma Tech Co., Ltd. Compounds and methods for treatment of hedgehog pathway associated conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1131688B (de) * 1960-12-16 1962-06-20 Hoechst Ag Verfahren zur Herstellung von Benzimidazolderivaten
NL6715600A (es) * 1966-12-02 1968-06-04
US3819640A (en) * 1972-08-07 1974-06-25 Degussa Aza-benzimidazoles and process for their production
EP0178413A1 (en) * 1984-08-17 1986-04-23 Beecham Group Plc Benzimidazoles
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles

Also Published As

Publication number Publication date
PT96792A (pt) 1991-10-31
NZ237121A (en) 1993-12-23
KR910021382A (ko) 1991-12-20
JPH05155858A (ja) 1993-06-22
US5124336A (en) 1992-06-23
LV11028B (en) 1996-06-20
ZA911061B (en) 1991-11-27
ES2080919T3 (es) 1996-02-16
EP0442820B1 (fr) 1995-09-13
US5021443A (en) 1991-06-04
CA2035710A1 (en) 1991-08-17
AU638096B2 (en) 1993-06-17
IL97191A (en) 1995-03-15
EP0442820A1 (fr) 1991-08-21
DK0442820T3 (da) 1996-02-05
FR2658511A1 (fr) 1991-08-23
AU7087491A (en) 1991-08-22
LV11028A (lv) 1996-02-20
ATE127794T1 (de) 1995-09-15
IE910339A1 (en) 1991-08-28
DE69112863D1 (de) 1995-10-19
GR3018000T3 (en) 1996-02-29
DE69112863T2 (de) 1996-03-28
FR2658511B1 (fr) 1992-06-19

Similar Documents

Publication Publication Date Title
IL97191A0 (en) Novel benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists,methods of preparation,synthesis intermediates and pharmaceutical compositions containing them
EA200600364A1 (ru) Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора
ATE183745T1 (de) Pyrido pyridazinon und pyridazinthionverbindungen mit pde iv inhibierender wirkung
FI884879A0 (fi) Terapeutiskt anvaendbara heterocykliska foereningar.
IL103944A0 (en) Piperazine derivatives,their preparation and pharmaceutical compositions containing them
IL107869A0 (en) Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
PT674621E (pt) Enantiomeros de derivados de carbazolo como agonistas do tipo 5-ht
DE69101141D1 (de) Neue Guanidinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
HUT44482A (en) Process for production of n-/-2-oxo-/n-/2methil-phenil/-n-benzil-amino/-ethil/-n-/2/-dimethil-amino/-ethil/-carbamates or ureids and medical preparatives containing such compounds
DE69015787D1 (de) Thiophenderivate, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
DE69409734D1 (de) Neue Derivate des 2-(1H)-Chinolinones, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
ES8203875A1 (es) Procedimiento para la preparacion de derivados de 2,3,4,5- tetrahidro-1-benzoxepin-3,5-diona
GR69358B (es)
ATE82972T1 (de) Thienyloxy-alkylamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
SE7412163L (es)
DK0765322T3 (da) Indolderivater som pro-drugs for 5-HT1-lignende receptoragonister
DK0553263T3 (da) 1'-Aminospiro[isoquinolin-4(1H),3'-pyrrolidin]-1,2',3,5'(2H)-tetroner samt analoge deraf til anvendelse som inhibitorer af
HU894471D0 (en) Process for the preparation of 15-amino-20,21-dinor-eburnamenine derivatives and pharmaceutical compositions containing them
HUP9802390A2 (hu) Imidazo-piridin származékok, ezeket tartalmazó gyógyászati készítmények, alkalmazásuk és intermedierek
TH15971A (th) อนุพันธ์ของแอมีน
DK0618917T3 (da) 1Amino-2- (benzothiazolyl)methyl spiro isoquinolin-4(1h),3-pyrrolidin -1,2,3,5(2h)-tetroner og analoger deraf, der kan anvendes som aldosereduktaseinhibitorer.